US FDA faces mounting criticism over Alzheimer’s drug approval

The Biogen Inc (BIIB.O) drug, Aduhelm, was authorised based on evidence that it can reduce brain plaques, a likely contributor to Alzheimer's, rather than proof that it slows progression of...